Hong Jiang

Cost-Effectiveness Analysis of 6 Tyrosine Kinase Inhibitors as First-Line Treatment for ALK-Positive NSCLC in China

Xueshan Sun, Zixuan Zhao, Bei Zheng, 2024, Clinical Medicine Insights. Oncology.